A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
A Phase 3, Randomized, Stratified, Observer-blind, Active-Controlled Study to Evaluate the Immunogenicity and Safety of mRNA-1010 Seasonal Influenza Vaccine in Adults 18 Years and Older
Sponsor: ModernaTX, Inc.
This PHASE3 trial investigates Seasonal Influenza and is currently completed. ModernaTX, Inc. leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 2 earlier versions
-
Sep 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE3
First recorded
Jun 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ModernaTX, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Acacías, Colombia , Adelaide, Australia , Aguazul, Colombia , Albion, Australia , Armenia, Colombia , Barranquilla, Colombia , Blacktown, Australia , Bogotá, Colombia , Brookvale, Australia , Bruce, Australia and 32 more locations